<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39043712</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein.</ArticleTitle><Pagination><StartPage>16895</StartPage><MedlinePgn>16895</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-66473-4</ELocationID><Abstract><AbstractText>SARS-CoV-2-contributes to sickness and death in COVID-19 patients partly by inducing a hyper-proinflammatory immune response in the host airway. This hyper-proinflammatory state involves activation of signaling by NF&#x3ba;B, and unexpectedly, ENaC, the epithelial sodium channel. Post-infection inflammation may also contribute to "Long COVID"/PASC. Enhanced signaling by NF&#x3ba;B and ENaC also marks the airway of patients suffering from cystic fibrosis, a life-limiting proinflammatory genetic disease due to inactivating mutations in the CFTR gene. We therefore hypothesized that inflammation in the COVID-19 airway might similarly be due to inhibition of CFTR signaling by SARS-CoV-2 spike protein, and therefore activation of both NF&#x3ba;B and ENaC signaling. We used western blot and electrophysiological techniques, and an organoid model of normal airway epithelia, differentiated on an air-liquid-interface (ALI). We found that CFTR protein expression and CFTR cAMP-activated chloride channel activity were lost when the model epithelium was exposed to SARS-CoV-2 spike proteins. As hypothesized, the absence of CFTR led to activation of both TNF&#x3b1;/NF&#x3ba;B signaling and &#x3b1; and &#x3b3; ENaC. We had previously shown that the cardiac glycoside drugs digoxin, digitoxin and ouabain blocked interaction of spike protein and ACE2. Consistently, addition of 30&#xa0;nM concentrations of the cardiac glycoside drugs, prevented loss of both CFTR protein and CFTR channel activity. ACE2 and CFTR were found to co-immunoprecipitate in both basal cells and differentiated epithelia. Thus spike-dependent CFTR loss might involve ACE2 as a bridge between Spike and CFTR. In addition, spike exposure to the epithelia resulted in failure of endosomal recycling to return CFTR to the plasma membrane. Thus, failure of CFTR recovery from endosomal recycling might be a mechanism for spike-dependent loss of CFTR. Finally, we found that authentic SARS-CoV-2 virus infection induced loss of CFTR protein, which was rescued by the cardiac glycoside drugs digitoxin and ouabain. Based on experiments with this organoid model of small airway epithelia, and comparisons with 16HBE14o- and other cell types expressing normal CFTR, we predict that inflammation in the COVID-19 airway may be mediated by inhibition of CFTR signaling by the SARS-CoV-2 spike protein, thus inducing a cystic fibrosis-like clinical phenotype. To our knowledge this is the first time COVID-19 airway inflammation has been experimentally traced in normal subjects to a contribution from SARS-CoV-2 spike-dependent inhibition of CFTR signaling.</AbstractText><CopyrightInformation>&#xa9; 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caohuy</LastName><ForeName>Hung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program (CHIRP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Health and Military Performance (CHAMP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eidelman</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program (CHIRP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tinghua</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program (CHIRP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Health and Military Performance (CHAMP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungunsukh</LastName><ForeName>Ognoon</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Health and Military Performance (CHAMP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Military Precision Health, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingfeng</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for the Study of Traumatic Stress (CSTS), and Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walton</LastName><ForeName>Nathan I</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program (CHIRP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Health and Military Performance (CHAMP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollard</LastName><ForeName>Bette S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Silver Pharmaceuticals, Rockville, MD, 20854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanal</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, 21702, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Geneva Foundation, Tacoma, WA, 98402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hentschel</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, 21702, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cherokee Nation Assurance, Catoosa, OK, 74015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florez</LastName><ForeName>Catalina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, 21702, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Geneva Foundation, Tacoma, WA, 98402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollard</LastName><ForeName>Harvey B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. harvey.pollard@usuhs.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program (CHIRP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. harvey.pollard@usuhs.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Health and Military Performance (CHAMP), Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. harvey.pollard@usuhs.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HU00012120068</GrantID><Agency>U.S. Department of Defense (United States Department of Defense)</Agency><Country/></Grant><Grant><GrantID>HU00011920047</GrantID><Agency>U.S. Department of Defense (United States Department of Defense)</Agency><Country/></Grant><Grant><GrantID>R01 HL167048</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IAA-AA-HL-14-007</GrantID><Agency>U.S. Department of Health and Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>1RO1HL167048</GrantID><Agency>U.S. Department of Health and Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)</Agency><Country/></Grant><Grant><GrantID>1RO1HL167048</GrantID><Agency>U.S. Department of Health and Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126880-72-6</RegistryNumber><NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505032">CFTR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053503">Epithelial Sodium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>5ACL011P69</RegistryNumber><NameOfSubstance UI="D010042">Ouabain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019005" MajorTopicYN="Y">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053503" MajorTopicYN="N">Epithelial Sodium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010042" MajorTopicYN="N">Ouabain</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>23</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39043712</ArticleId><ArticleId IdType="pmc">PMC11266487</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-66473-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-66473-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig.130, 2620&#x2013;2629. 10.1172/jci137244 (2020). 10.1172/jci137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe27, 883-890.e882. 10.1016/j.chom.2020.04.017 (2020). 10.1016/j.chom.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet395, 497&#x2013;506. 10.1016/s0140-6736(20)30183-5 (2020). 10.1016/s0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev.76, 16&#x2013;32. 10.1128/mmbr.05015-11 (2012). 10.1128/mmbr.05015-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mmbr.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar, R. &amp; Perlman, S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol.39, 529&#x2013;539. 10.1007/s00281-017-0629-x (2017). 10.1007/s00281-017-0629-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDiego, M. L. et al. Inhibition of NF-&#x3ba;B-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol.88, 913&#x2013;924. 10.1128/jvi.02576-13 (2014). 10.1128/jvi.02576-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02576-13</ArticleId><ArticleId IdType="pmc">PMC3911641</ArticleId><ArticleId IdType="pubmed">24198408</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, C. M., Wang, L. &amp; Yoo, D. Activation of NF-&#x3ba;B and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci. Rep.11, 13464. 10.1038/s41598-021-92941-2 (2021). 10.1038/s41598-021-92941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92941-2</ArticleId><ArticleId IdType="pmc">PMC8242070</ArticleId><ArticleId IdType="pubmed">34188167</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand, P., Puranik, A., Aravamudan, M., Venkatakrishnan, A. J. &amp; Soundararajan, V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. eLife9. 10.7554/eLife.58603 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343387</ArticleId><ArticleId IdType="pubmed">32452762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentzsch, M. &amp; Rossier, B. C. A Pathophysiological model for COVID-19: Critical importance of transepithelial sodium transport upon airway infection. Function (Oxf)1, zqaa024. 10.1093/function/zqaa024 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662147</ArticleId><ArticleId IdType="pubmed">33201937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q., Lenardo, M. J. &amp; Baltimore, D. 30 years of NF-kappaB: A blossoming of relevance to human pathobiology. Cell168, 37&#x2013;57. 10.1016/j.cell.2016.12.012 (2017). 10.1016/j.cell.2016.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.12.012</ArticleId><ArticleId IdType="pmc">PMC5268070</ArticleId><ArticleId IdType="pubmed">28086098</ArticleId></ArticleIdList></Reference><Reference><Citation>Reusch, N. et al. Neutrophils in COVID-19. Front. Immunol.12, 652470. 10.3389/fimmu.2021.652470 (2021). 10.3389/fimmu.2021.652470</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.652470</ArticleId><ArticleId IdType="pmc">PMC8027077</ArticleId><ArticleId IdType="pubmed">33841435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua, R. L. et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol.38, 970&#x2013;979. 10.1038/s41587-020-0602-4 (2020). 10.1038/s41587-020-0602-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0602-4</ArticleId><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs, C. A. et al. Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures. Am. J. Physiol. Lung Cell. Mol. Physiol.305, L990&#x2013;L1001. 10.1152/ajplung.00103.2013 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882538</ArticleId><ArticleId IdType="pubmed">24124190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mall, M. A. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. Eur. Respir. J.56, 1. 10.1183/13993003.00946-2020 (2020).10.1183/13993003.00946-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00946-2020</ArticleId><ArticleId IdType="pmc">PMC7758539</ArticleId><ArticleId IdType="pubmed">32732328</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal, A. D. &amp; VanElzakker, M. B. Long COVID or post-acute Sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol.12, 698169. 10.3389/fmicb.2021.698169 (2021). 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow, D. et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Res. Square. 10.21203/rs.3.rs-1139035/v1 (2021).</Citation></Reference><Reference><Citation>Al-Aly, Z., Xie, Y. &amp; Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature594, 259&#x2013;264. 10.1038/s41586-021-03553-9 (2021). 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret, N. et al. Immunology of COVID-19: Current State of the Science. Immunity52, 910&#x2013;941. 10.1016/j.immuni.2020.05.002 (2020). 10.1016/j.immuni.2020.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeldt, C. J. et al. SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-&#x3ba;B. Commun. Biol.5, 45. 10.1038/s42003-021-02983-5 (2022). 10.1038/s42003-021-02983-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02983-5</ArticleId><ArticleId IdType="pmc">PMC8755718</ArticleId><ArticleId IdType="pubmed">35022513</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond, M. S. &amp; Kanneganti, T. D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol.23, 165&#x2013;176. 10.1038/s41590-021-01091-0 (2022). 10.1038/s41590-021-01091-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, J. et al. SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function. J. Med. Virol.95, e28175. 10.1002/jmv.28175 (2023). 10.1002/jmv.28175</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28175</ArticleId><ArticleId IdType="pmc">PMC9538343</ArticleId><ArticleId IdType="pubmed">36163413</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki, R. &amp; Kanneganti, T. D. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J. Transl. Med.20, 542. 10.1186/s12967-022-03767-z (2022). 10.1186/s12967-022-03767-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03767-z</ArticleId><ArticleId IdType="pmc">PMC9682745</ArticleId><ArticleId IdType="pubmed">36419185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvet, M. et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathogens6, e1000863. 10.1371/journal.ppat.1000863 (2010). 10.1371/journal.ppat.1000863</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000863</ArticleId><ArticleId IdType="pmc">PMC2858705</ArticleId><ArticleId IdType="pubmed">20421945</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, X. et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc. Natl. Acad. Sci. USA114, E4251-e4260. 10.1073/pnas.1618310114 (2017). 10.1073/pnas.1618310114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618310114</ArticleId><ArticleId IdType="pmc">PMC5448190</ArticleId><ArticleId IdType="pubmed">28484023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackbart, M., Deng, X. &amp; Baker, S. C. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl. Acad. Sci. USA117, 8094&#x2013;8103. 10.1073/pnas.1921485117 (2020). 10.1073/pnas.1921485117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1921485117</ArticleId><ArticleId IdType="pmc">PMC7149396</ArticleId><ArticleId IdType="pubmed">32198201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov, K. A. et al. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol.78, 5619&#x2013;5632. 10.1128/jvi.78.11.5619-5632.2004 (2004). 10.1128/jvi.78.11.5619-5632.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.78.11.5619-5632.2004</ArticleId><ArticleId IdType="pmc">PMC415832</ArticleId><ArticleId IdType="pubmed">15140959</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoops, K. et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol.6, e226. 10.1371/journal.pbio.0060226 (2008). 10.1371/journal.pbio.0060226</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060226</ArticleId><ArticleId IdType="pmc">PMC2535663</ArticleId><ArticleId IdType="pubmed">18798692</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. Y. et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res.286, 198074. 10.1016/j.virusres.2020.198074 (2020). 10.1016/j.virusres.2020.198074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198074</ArticleId><ArticleId IdType="pmc">PMC7309931</ArticleId><ArticleId IdType="pubmed">32589897</ArticleId></ArticleIdList></Reference><Reference><Citation>Caohuy, H. et al. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells. Sci. Rep.11, 22195. 10.1038/s41598-021-01690-9 (2021). 10.1038/s41598-021-01690-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01690-9</ArticleId><ArticleId IdType="pmc">PMC8589851</ArticleId><ArticleId IdType="pubmed">34773067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, J. et al. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Sci. Rep.10, 16200. 10.1038/s41598-020-72879-7 (2020). 10.1038/s41598-020-72879-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72879-7</ArticleId><ArticleId IdType="pmc">PMC7530981</ArticleId><ArticleId IdType="pubmed">33004837</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdiev, B. K., Qadri, Y. J. &amp; Benos, D. J. Assessment of the CFTR and ENaC association. Mol. Biosyst.5, 123&#x2013;127. 10.1039/b810471a (2009). 10.1039/b810471a</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b810471a</ArticleId><ArticleId IdType="pmc">PMC2666849</ArticleId><ArticleId IdType="pubmed">19156256</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Hameid, R., Cormet-Boyaka, E., Kuebler, W. M., Uddin, M. &amp; Berdiev, B. K. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Am. J. Physiol. Lung Cell. Mol. Physiol.320, L430&#x2013;L435. 10.1152/ajplung.00499.2020 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938641</ArticleId><ArticleId IdType="pubmed">33434105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. et al. CFTR controls the activity of NF-kappaB by enhancing the degradation of TRADD. Cell. Physiol. Biochem.40, 1063&#x2013;1078. 10.1159/000453162 (2016). 10.1159/000453162</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000453162</ArticleId><ArticleId IdType="pmc">PMC7067292</ArticleId><ArticleId IdType="pubmed">27960153</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Q. et al. Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients. Respir. Res.20, 290. 10.1186/s12931-019-1214-8 (2019). 10.1186/s12931-019-1214-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-019-1214-8</ArticleId><ArticleId IdType="pmc">PMC6925517</ArticleId><ArticleId IdType="pubmed">31864360</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, M. et al. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc. Natl. Acad. Sci. USA101, 7693&#x2013;7698. 10.1073/pnas.0402030101 (2004). 10.1073/pnas.0402030101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402030101</ArticleId><ArticleId IdType="pmc">PMC419668</ArticleId><ArticleId IdType="pubmed">15136726</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton, B. A., Hampton, T. H. &amp; Ashare, A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol.319, L408-L415. 10.1152/ajplung.00225.2020 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518058</ArticleId><ArticleId IdType="pubmed">32668165</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckham, D., McDermott, M. F., Savic, S. &amp; Mehta, A. COVID-19 meets Cystic Fibrosis: For better or worse?. Genes Immunity21, 260&#x2013;262. 10.1038/s41435-020-0103-y (2020). 10.1038/s41435-020-0103-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41435-020-0103-y</ArticleId><ArticleId IdType="pubmed">32606316</ArticleId></ArticleIdList></Reference><Reference><Citation>Scambler, T. et al. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. eLife8. 10.7554/eLife.49248 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764826</ArticleId><ArticleId IdType="pubmed">31532390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzerri, V. et al. SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation. Nat. Commun.14, 132. 10.1038/s41467-023-35862-0 (2023). 10.1038/s41467-023-35862-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-35862-0</ArticleId><ArticleId IdType="pmc">PMC9830623</ArticleId><ArticleId IdType="pubmed">36627352</ArticleId></ArticleIdList></Reference><Reference><Citation>Caohuy, H. et al. Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 Spike protein. bioRxiv. 10.1101/2022.01.18.476803 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11266487</ArticleId><ArticleId IdType="pubmed">39043712</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters, M. S. et al. Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir. Res.14, 135. 10.1186/1465-9921-14-135 (2013). 10.1186/1465-9921-14-135</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-14-135</ArticleId><ArticleId IdType="pmc">PMC3907041</ArticleId><ArticleId IdType="pubmed">24298994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. Characterization of an immortalized human small airway basal stem/progenitor cell line with airway region-specific differentiation capacity. Respir. Res.20, 196. 10.1186/s12931-019-1140-9 (2019). 10.1186/s12931-019-1140-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-019-1140-9</ArticleId><ArticleId IdType="pmc">PMC6708250</ArticleId><ArticleId IdType="pubmed">31443657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium. Am. J. Respir. Crit. Care Med.202, 219&#x2013;229. 10.1164/rccm.202003-0541OC (2020). 10.1164/rccm.202003-0541OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0541OC</ArticleId><ArticleId IdType="pmc">PMC7365377</ArticleId><ArticleId IdType="pubmed">32432483</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoumacher, R. A. et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA87, 4012&#x2013;4016 (1990). 10.1073/pnas.87.10.4012</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.10.4012</ArticleId><ArticleId IdType="pmc">PMC54034</ArticleId><ArticleId IdType="pubmed">1692630</ArticleId></ArticleIdList></Reference><Reference><Citation>Caohuy, H. et al. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of DeltaF508-cystic fibrosis transmembrane conductance regulator (DeltaF508-CFTR). J. Biol. Chem.289, 35953&#x2013;35968. 10.1074/jbc.M114.598649 (2014). 10.1074/jbc.M114.598649</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.598649</ArticleId><ArticleId IdType="pmc">PMC4276863</ArticleId><ArticleId IdType="pubmed">25384981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol.7, e1000155. 10.1371/journal.pbio.1000155 (2009). 10.1371/journal.pbio.1000155</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000155</ArticleId><ArticleId IdType="pmc">PMC2705187</ArticleId><ArticleId IdType="pubmed">19621064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, M. et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. Cell Biol.164, 923&#x2013;933. 10.1083/jcb.200312018 (2004). 10.1083/jcb.200312018</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200312018</ArticleId><ArticleId IdType="pmc">PMC2172283</ArticleId><ArticleId IdType="pubmed">15007060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameen, N., Silvis, M. &amp; Bradbury, N. A. Endocytic trafficking of CFTR in health and disease. J. Cyst. Fibrosis.6, 1&#x2013;14. 10.1016/j.jcf.2006.09.002 (2007).10.1016/j.jcf.2006.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2006.09.002</ArticleId><ArticleId IdType="pmc">PMC1964799</ArticleId><ArticleId IdType="pubmed">17098482</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomberger, J. M., Guggino, W. B. &amp; Stanton, B. A. Methods to monitor cell surface expression and endocytic trafficking of CFTR in polarized epithelial cells. Methods Mol. Biol. (Clifton, N.J.)741, 271&#x2013;283. 10.1007/978-1-61779-117-8_18 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402161</ArticleId><ArticleId IdType="pubmed">21594791</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Caballero, A., Dang, Y., He, H. &amp; Stutts, M. J. ENaC proteolytic regulation by channel-activating protease 2. J. Gen. Physiol.132, 521&#x2013;535. 10.1085/jgp.200810030 (2008). 10.1085/jgp.200810030</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.200810030</ArticleId><ArticleId IdType="pmc">PMC2571966</ArticleId><ArticleId IdType="pubmed">18852303</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerteis, S. et al. Proteolytic activation of the epithelial sodium channel (ENaC) by the cysteine protease cathepsin-S. Pflugers Archiv Eur. J. Physiol.464, 353&#x2013;365. 10.1007/s00424-012-1138-3 (2012). 10.1007/s00424-012-1138-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-012-1138-3</ArticleId><ArticleId IdType="pmc">PMC3448907</ArticleId><ArticleId IdType="pubmed">22864553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schillers, H., Shahin, V., Albermann, L., Schafer, C. &amp; Oberleithner, H. Imaging CFTR: A tail to tail dimer with a central pore. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.14, 1&#x2013;10. 10.1159/000076921 (2004).10.1159/000076921</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000076921</ArticleId><ArticleId IdType="pubmed">14976401</ArticleId></ArticleIdList></Reference><Reference><Citation>Schillers, H. Imaging CFTR in its native environment. Pflugers Archiv. Eur. J. Physiol.456, 163&#x2013;177. 10.1007/s00424-007-0399-8 (2008). 10.1007/s00424-007-0399-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-007-0399-8</ArticleId><ArticleId IdType="pubmed">18057957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Aleksandrov, L. A., Riordan, J. R. &amp; Ford, R. C. Domain location within the cystic fibrosis transmembrane conductance regulator protein investigated by electron microscopy and gold labelling. Biochim. Biophys. Acta1808, 399&#x2013;404. 10.1016/j.bbamem.2010.08.012 (2011). 10.1016/j.bbamem.2010.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2010.08.012</ArticleId><ArticleId IdType="pubmed">20727849</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, C., Roy, K., Dandridge, K. &amp; Naren, A. P. Molecular assembly of cystic fibrosis transmembrane conductance regulator in plasma membrane. J. Biol. Chem.279, 24673&#x2013;24684. 10.1074/jbc.M400688200 (2004). 10.1074/jbc.M400688200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M400688200</ArticleId><ArticleId IdType="pubmed">15060073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Q. et al. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc. Natl. Acad. Sci. USA102, 9631&#x2013;9636. 10.1073/pnas.0504097102 (2005). 10.1073/pnas.0504097102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504097102</ArticleId><ArticleId IdType="pmc">PMC1160519</ArticleId><ArticleId IdType="pubmed">15983368</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, B. S., Blanco, J. C. &amp; Pollard, J. R. Classical drug digitoxin inhibits influenza cytokine storm, with implications for covid-19 therapy. In vivo (Athens, Greece)34, 3723&#x2013;3730. 10.21873/invivo.12221 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811644</ArticleId><ArticleId IdType="pubmed">33144490</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, S. C. et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem. Pharmacol.79, 1272&#x2013;1280. 10.1016/j.bcp.2009.12.021 (2010). 10.1016/j.bcp.2009.12.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2009.12.021</ArticleId><ArticleId IdType="pmc">PMC2834878</ArticleId><ArticleId IdType="pubmed">20067776</ArticleId></ArticleIdList></Reference><Reference><Citation>Veit, G. et al. From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations. Mol. Biol. Cell27, 424&#x2013;433. 10.1091/mbc.E14-04-0935 (2016). 10.1091/mbc.E14-04-0935</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E14-04-0935</ArticleId><ArticleId IdType="pmc">PMC4751594</ArticleId><ArticleId IdType="pubmed">26823392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel, S. E., Brigman, K. N., Koller, B. H., Boucher, R. C. &amp; Stutts, M. J. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science (New York, N.Y.)266, 107&#x2013;109. 10.1126/science.7524148 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7524148</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell, B. C. et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc. Natl. Acad. Sci. USA88, 6565&#x2013;6569. 10.1073/pnas.88.15.6565 (1991). 10.1073/pnas.88.15.6565</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.15.6565</ArticleId><ArticleId IdType="pmc">PMC52127</ArticleId><ArticleId IdType="pubmed">1713683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wine, J. J. How the sweat gland reveals levels of CFTR activity. J. Cyst. Fibrosis.21, 396&#x2013;406. 10.1016/j.jcf.2022.02.001 (2022).10.1016/j.jcf.2022.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2022.02.001</ArticleId><ArticleId IdType="pubmed">35184981</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;olak, Y., Nordestgaard, B. G. &amp; Afzal, S. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur. Respir. J.56, 1. 10.1183/13993003.00558-2020 (2020).10.1183/13993003.00558-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00558-2020</ArticleId><ArticleId IdType="pubmed">32398304</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, A. C. et al. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc. Natl. Acad. Sci. USA117, 1621&#x2013;1627. 10.1073/pnas.1914912117 (2020). 10.1073/pnas.1914912117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1914912117</ArticleId><ArticleId IdType="pmc">PMC6983448</ArticleId><ArticleId IdType="pubmed">31882447</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarri, M. et al. Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants. J. Pers. Med.11. 10.3390/jpm11060558 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8232773</ArticleId><ArticleId IdType="pubmed">34203982</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbi, C., Renieri, A. &amp; Strandvik, B. Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries. J. Infect.10.1016/j.jinf.2022.06.006 (2022). 10.1016/j.jinf.2022.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.06.006</ArticleId><ArticleId IdType="pmc">PMC9188282</ArticleId><ArticleId IdType="pubmed">35700866</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarri, M. et al. Gain- and Loss-of-function CFTR alleles are associated with COVID-19 clinical outcomes. Cells11. 10.3390/cells11244096 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9776607</ArticleId><ArticleId IdType="pubmed">36552859</ArticleId></ArticleIdList></Reference><Reference><Citation>Terlizzi, V., Motisi, M. A., Pellegrino, R., Padoan, R. &amp; Chiappini, E. Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review. Front. Pediatr.10, 958658. 10.3389/fped.2022.958658 (2022). 10.3389/fped.2022.958658</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.958658</ArticleId><ArticleId IdType="pmc">PMC9393295</ArticleId><ArticleId IdType="pubmed">36003489</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot, L. et al. Lung disease modifier genes in cystic fibrosis. Int. J. Biochem. Cell Biol.52, 83&#x2013;93. 10.1016/j.biocel.2014.02.011 (2014). 10.1016/j.biocel.2014.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2014.02.011</ArticleId><ArticleId IdType="pubmed">24569122</ArticleId></ArticleIdList></Reference><Reference><Citation>Beucher, J. et al. AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis. PloS one7, e41913. 10.1371/journal.pone.0041913 (2012). 10.1371/journal.pone.0041913</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041913</ArticleId><ArticleId IdType="pmc">PMC3408394</ArticleId><ArticleId IdType="pubmed">22860029</ArticleId></ArticleIdList></Reference><Reference><Citation>Drumm, M. L. et al. Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med.353, 1443&#x2013;1453. 10.1056/NEJMoa051469 (2005). 10.1056/NEJMoa051469</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051469</ArticleId><ArticleId IdType="pubmed">16207846</ArticleId></ArticleIdList></Reference><Reference><Citation>Marson, F. A., Bertuzzo, C. S., Ribeiro, A. F. &amp; Ribeiro, J. D. Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: A cross-sectional study. BMC Med. Genet.15, 27. 10.1186/1471-2350-15-27 (2014). 10.1186/1471-2350-15-27</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2350-15-27</ArticleId><ArticleId IdType="pmc">PMC3973994</ArticleId><ArticleId IdType="pubmed">24593045</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho, C. A. et al. TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis. Int. J. Mol. Epidemiol. Genet.5, 87&#x2013;99 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065397</ArticleId><ArticleId IdType="pubmed">24959313</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan, L. L. et al. IL8 gene as modifier of cystic fibrosis: Unraveling the factors which influence clinical variability. Hum. Genet.135, 881&#x2013;894. 10.1007/s00439-016-1684-4 (2016). 10.1007/s00439-016-1684-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-016-1684-4</ArticleId><ArticleId IdType="pubmed">27209008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutting, G. R. Modifier genes in Mendelian disorders: The example of cystic fibrosis. Ann. N. Y. Acad. Sci.1214, 57&#x2013;69. 10.1111/j.1749-6632.2010.05879.x (2010). 10.1111/j.1749-6632.2010.05879.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2010.05879.x</ArticleId><ArticleId IdType="pmc">PMC3040597</ArticleId><ArticleId IdType="pubmed">21175684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton, N. I. et al. Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients. Physiol. Rep.9, e14886. 10.14814/phy2.14886 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8176904</ArticleId><ArticleId IdType="pubmed">34086412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.)367, 1444&#x2013;1448. 10.1126/science.abb2762 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q., Gefter, J., Sneddon, W. B., Mamonova, T. &amp; Friedman, P. A. ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion. iScience24, 102770. 10.1016/j.isci.2021.102770 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223119</ArticleId><ArticleId IdType="pubmed">34189428</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillet-Saguy, C. &amp; Wolff, N. PDZ-containing proteins targeted by the ACE2 receptor. Viruses13. 10.3390/v13112281 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624105</ArticleId><ArticleId IdType="pubmed">34835087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, R. A. et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc. Natl. Acad. Sci. USA95, 8496&#x2013;8501. 10.1073/pnas.95.15.8496 (1998). 10.1073/pnas.95.15.8496</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.15.8496</ArticleId><ArticleId IdType="pmc">PMC21104</ArticleId><ArticleId IdType="pubmed">9671706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B. &amp; Li, M. Peptide binding consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR). FEBS Lett.427, 103&#x2013;108. 10.1016/s0014-5793(98)00402-5 (1998). 10.1016/s0014-5793(98)00402-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(98)00402-5</ArticleId><ArticleId IdType="pubmed">9613608</ArticleId></ArticleIdList></Reference><Reference><Citation>Benharouga, M. et al. The role of the C terminus and Na+/H+ exchanger regulatory factor in the functional expression of cystic fibrosis transmembrane conductance regulator in nonpolarized cells and epithelia. J. Biol. Chem.278, 22079&#x2013;22089. 10.1074/jbc.M301030200 (2003). 10.1074/jbc.M301030200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M301030200</ArticleId><ArticleId IdType="pubmed">12651858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon, S. H., Pollard, H. &amp; Guggino, W. B. Knockdown of NHERF1 enhances degradation of temperature rescued DeltaF508 CFTR from the cell surface of human airway cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.20, 763&#x2013;772. 10.1159/000110436 (2007).10.1159/000110436</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110436</ArticleId><ArticleId IdType="pubmed">17982258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W., Zhang, Z., Zhang, Y. &amp; Naren, A. P. CFTR-NHERF2-LPA&#x2082; complex in the airway and gut epithelia. Int. J. Mol. Sci.18. 10.3390/ijms18091896 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618545</ArticleId><ArticleId IdType="pubmed">28869532</ArticleId></ArticleIdList></Reference><Reference><Citation>Naren, A. P. et al. A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc. Natl. Acad. Sci. USA100, 342&#x2013;346. 10.1073/pnas.0135434100 (2003). 10.1073/pnas.0135434100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0135434100</ArticleId><ArticleId IdType="pmc">PMC140971</ArticleId><ArticleId IdType="pubmed">12502786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S., Yue, H., Derin, R. B., Guggino, W. B. &amp; Li, M. Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. Cell103, 169&#x2013;179. 10.1016/s0092-8674(00)00096-9 (2000). 10.1016/s0092-8674(00)00096-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)00096-9</ArticleId><ArticleId IdType="pubmed">11051556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitlin, P. L. et al. Digitoxin for airway inflammation in cystic fibrosis: Preliminary assessment of safety, pharmacokinetics, and dose finding. Ann. Am. Thorac. Soc.14, 220&#x2013;229. 10.1513/AnnalsATS.201608-649OC (2017). 10.1513/AnnalsATS.201608-649OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201608-649OC</ArticleId><ArticleId IdType="pmc">PMC5427734</ArticleId><ArticleId IdType="pubmed">28006108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman, B. J. &amp; Bigger, J. Digitalis and Allied Cardiac Glycosides Goodman and Gilman's The Pharmacological Basis of Therapeutics Eith Edition edn, 833 (Permagon Press, 1990).</Citation></Reference><Reference><Citation>Mason, D. T. &amp; Braunwald, E. Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J. Clin. Investig.43, 532&#x2013;543. 10.1172/jci104939 (1964). 10.1172/jci104939</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci104939</ArticleId><ArticleId IdType="pmc">PMC441947</ArticleId><ArticleId IdType="pubmed">14135505</ArticleId></ArticleIdList></Reference><Reference><Citation>Selden, R. &amp; Smith, T. W. Ouabain pharmacokinetics in dog and man. Determination by radioimmunoassay. Circulation45, 1176&#x2013;1182. 10.1161/01.cir.45.6.1176 (1972). 10.1161/01.cir.45.6.1176</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.45.6.1176</ArticleId><ArticleId IdType="pubmed">5032817</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates, A. L., Desmond, K., Asher, M. I., Hortop, J. &amp; Beaudry, P. H. The effect of digoxin on exercise capacity and exercising cardiac function in cystic fibrosis. Chest82, 543&#x2013;547 (1982). 10.1378/chest.82.5.543</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.82.5.543</ArticleId><ArticleId IdType="pubmed">7128221</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss, A. J. et al. Absorption of digoxin in children with cystic fibrosis. J. Pediatr.86, 295&#x2013;297 (1975). 10.1016/S0022-3476(75)80493-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(75)80493-8</ArticleId><ArticleId IdType="pubmed">1111698</ArticleId></ArticleIdList></Reference><Reference><Citation>Selzer, A., Hultgren, H. N., Ebnother, C. L., Bradley, H. W. &amp; Stone, A. O. Efect of digoxin on the circulation in normal man. Br. Heart J.21, 335&#x2013;342. 10.1136/hrt.21.3.335 (1959). 10.1136/hrt.21.3.335</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.21.3.335</ArticleId><ArticleId IdType="pmc">PMC1017589</ArticleId><ArticleId IdType="pubmed">14444797</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, M. H. Jr., Zohman, L. R. &amp; Ratner, A. C. Hemodynamic effects of cardiac glycosides on normal human subjects during rest and exercise. J. Appl. Physiol.13, 417&#x2013;421. 10.1152/jappl.1958.13.3.417 (1958). 10.1152/jappl.1958.13.3.417</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1958.13.3.417</ArticleId><ArticleId IdType="pubmed">13587425</ArticleId></ArticleIdList></Reference><Reference><Citation>Banaag, A. L., Pollard, H. B. &amp; Koehlmoos, T. P. Digoxin and standard-of-care therapy for heart failure patients with COVID-19: Analysis of data from the US military health system (MHS) data repository. Drugs Real World Outcomes 1&#x2013;9. 10.1007/s40801-023-00360-8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10024520</ArticleId><ArticleId IdType="pubmed">36933173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, S. M. et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J. Gen. Intern. Med. 1&#x2013;8. 10.1007/s11606-022-07523-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Agergaard, J., Gunst, J. D., Schi&#xf8;ttz-Christensen, B., &#xd8;stergaard, L. &amp; Wejse, C. Long-term Prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as omicron variants. Int. J. Infect. Dis.. 10.1016/j.ijid.2023.10.022 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37907167</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21, 133&#x2013;146. 10.1038/s41579-022-00846-2 (2023). 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema, K. L. et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among US veterans: Target trial emulation studies with one-month and six-month outcomes. Ann. Intern. Med.176, 807&#x2013;816. 10.7326/m22-3565 (2023). 10.7326/m22-3565</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m22-3565</ArticleId><ArticleId IdType="pmc">PMC10243488</ArticleId><ArticleId IdType="pubmed">37276589</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberis, E. et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Front. Mol. Biosci.8, 632290. 10.3389/fmolb.2021.632290 (2021). 10.3389/fmolb.2021.632290</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.632290</ArticleId><ArticleId IdType="pmc">PMC7937875</ArticleId><ArticleId IdType="pubmed">33693030</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesce, E. et al. Exosomes recovered from the plasma of COVID-19 patients expose SARS-CoV-2 spike-derived fragments and contribute to the adaptive immune response. Front. Immunol.12, 785941. 10.3389/fimmu.2021.785941 (2021). 10.3389/fimmu.2021.785941</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.785941</ArticleId><ArticleId IdType="pmc">PMC8801440</ArticleId><ArticleId IdType="pubmed">35111156</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann. Neurol.91, 772&#x2013;781. 10.1002/ana.26350 (2022). 10.1002/ana.26350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker, L. M. et al. Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis. Circulation147, 867&#x2013;876. 10.1161/circulationaha.122.061025 (2023). 10.1161/circulationaha.122.061025</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.122.061025</ArticleId><ArticleId IdType="pmc">PMC10010667</ArticleId><ArticleId IdType="pubmed">36597886</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z. et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin. Infect. Dis.76, e487&#x2013;e490. 10.1093/cid/ciac722 (2023). 10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheppke, K. A. et al. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. Am. J. Emerg. Med.75, 122&#x2013;127. 10.1016/j.ajem.2023.09.051 (2024). 10.1016/j.ajem.2023.09.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2023.09.051</ArticleId><ArticleId IdType="pubmed">37944296</ArticleId></ArticleIdList></Reference><Reference><Citation>Warth, J. D. et al. CFTR chloride channels in human and simian heart. Cardiovasc. Res.31, 615&#x2013;624 (1996). 10.1016/S0008-6363(95)00245-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-6363(95)00245-6</ArticleId><ArticleId IdType="pubmed">8689654</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales, M. M. et al. Both the wild type and a functional isoform of CFTR are expressed in kidney. Am. J. Physiol.270, F1038-1048. 10.1152/ajprenal.1996.270.6.F1038 (1996). 10.1152/ajprenal.1996.270.6.F1038</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.1996.270.6.F1038</ArticleId><ArticleId IdType="pubmed">8764323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Y., Su, M., McNutt, M. A. &amp; Gu, J. Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain. J. Histochem. Cytochem.57, 1113&#x2013;1120. 10.1369/jhc.2009.953455 (2009). 10.1369/jhc.2009.953455</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.2009.953455</ArticleId><ArticleId IdType="pmc">PMC2778084</ArticleId><ArticleId IdType="pubmed">19654104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidington, D. et al. CFTR therapeutics normalize cerebral perfusion deficits in mouse models of heart failure and subarachnoid hemorrhage. JACC Basic Transl. Sci.4, 940&#x2013;958. 10.1016/j.jacbts.2019.07.004 (2019). 10.1016/j.jacbts.2019.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2019.07.004</ArticleId><ArticleId IdType="pmc">PMC6939007</ArticleId><ArticleId IdType="pubmed">31909302</ArticleId></ArticleIdList></Reference><Reference><Citation>Storstein, L., Nore, A. K. &amp; Sjaastad, O. Studies on digitalis. 23. Blood-brain barrier of digitoxin in humans. Clin. Cardiol.2, 146&#x2013;150 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantin, A. M. et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am. J. Respir. Crit. Care Med.173, 1139&#x2013;1144. 10.1164/rccm.200508-1330OC (2006). 10.1164/rccm.200508-1330OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200508-1330OC</ArticleId><ArticleId IdType="pubmed">16497995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rab, A. et al. Cigarette smoke and CFTR: Implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell. Mol. Physiol.305, L530-541. 10.1152/ajplung.00039.2013 (2013). 10.1152/ajplung.00039.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00039.2013</ArticleId><ArticleId IdType="pmc">PMC3798775</ArticleId><ArticleId IdType="pubmed">23934925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Fernandez, E., De Santi, C., De Rose, V. &amp; Greene, C. M. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. Expert Rev. Respir. Med.12, 483&#x2013;492. 10.1080/17476348.2018.1475235 (2018). 10.1080/17476348.2018.1475235</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2018.1475235</ArticleId><ArticleId IdType="pubmed">29750581</ArticleId></ArticleIdList></Reference><Reference><Citation>Courville, C. A. et al. Acquired defects in CFTR-dependent beta-adrenergic sweat secretion in chronic obstructive pulmonary disease. Respir. Res.15, 25. 10.1186/1465-9921-15-25 (2014). 10.1186/1465-9921-15-25</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-15-25</ArticleId><ArticleId IdType="pmc">PMC4015030</ArticleId><ArticleId IdType="pubmed">24568560</ArticleId></ArticleIdList></Reference><Reference><Citation>Londino, J. D. et al. Influenza virus M2 targets cystic fibrosis transmembrane conductance regulator for lysosomal degradation during viral infection. FASEB J.29, 2712&#x2013;2725. 10.1096/fj.14-268755 (2015). 10.1096/fj.14-268755</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-268755</ArticleId><ArticleId IdType="pmc">PMC4478808</ArticleId><ArticleId IdType="pubmed">25795456</ArticleId></ArticleIdList></Reference><Reference><Citation>Londino, J. D. et al. Influenza virus infection alters ion channel function of airway and alveolar cells: mechanisms and physiological sequelae. Am. J. Physiol. Lung Cell. Mol. Physiol.313, L845&#x2013;l858. 10.1152/ajplung.00244.2017 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792181</ArticleId><ArticleId IdType="pubmed">28775098</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, B. S., Blanco, J. C., Pollard, J. R. &amp; Prince, G. A. Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy. bioRxiv. 10.1101/2020.04.09.034983 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811644</ArticleId><ArticleId IdType="pubmed">33144490</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki, R. et al. Synergism of TNF-&#x3b1; and IFN-&#x3b3; triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell184, 149-168.e117. 10.1016/j.cell.2020.11.025 (2021). 10.1016/j.cell.2020.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.025</ArticleId><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales, L., Oliveros, J. C., Enjuanes, L. &amp; Sola, I. Contribution of Host miRNA-223&#x2013;3p to SARS-CoV-induced lung inflammatory pathology. mBio13, e0313521. 10.1128/mbio.03135-21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941895</ArticleId><ArticleId IdType="pubmed">35229638</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner, A. et al. Tumor necrosis factor-&#x3b1;-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure. Circulation125, 2739&#x2013;2750. 10.1161/circulationaha.111.047316 (2012). 10.1161/circulationaha.111.047316</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.111.047316</ArticleId><ArticleId IdType="pubmed">22534621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>